ライフサイエンスコーパス: eosinophilic

1 gorized into the four phenotypes as follows: eosinophilic (40%), mixed (6.7%), neutrophilic (5.4%) an

2 agged 2 single- or double-deficient mice had eosinophilic airway inflammation and a TH2 cell activati

3 rmine whether gammaT supplementation reduces eosinophilic airway inflammation and acute neutrophilic

4 and their cytokine production, and promoted eosinophilic airway inflammation and goblet cell hyperpl

5 xposure, rhinovirus-induced neutrophilic and eosinophilic airway inflammation and hyperresponsiveness

6 Fevipiprant reduces eosinophilic airway inflammation and is well tolerated i

7 miR-155(-/-) mice showed reduced eosinophilic airway inflammation compared to WT mice in

8 This finding suggests that eosinophilic airway inflammation contributes to COPD exa

9 The level of eosinophilic airway inflammation correlates with variati

10 has predictive value for the development of eosinophilic airway inflammation in asthmatic children a

11 ide (FENO) is a useful noninvasive marker of eosinophilic airway inflammation in asthmatics.

12 Exposure to aeroallergens induces eosinophilic airway inflammation in patients with asthma

13 Lipopolysaccharide promotes eosinophilic airway inflammation in patients with asthma

14 of prostaglandin D2 receptor 2, might reduce eosinophilic airway inflammation in patients with modera

15 Vitamin D supplementation reduced eosinophilic airway inflammation in patients with nonato

16 The extent to which eosinophilic airway inflammation in severe asthma respon

17 Eosinophilic airway inflammation is often present in ast

18 HDM extract used, but did not aggravate the eosinophilic airway inflammation or airway hyper-reactiv

19 merican subjects were more likely to exhibit eosinophilic airway inflammation than white subjects in

20 HDM application led to TH2 sensitization and eosinophilic airway inflammation upon intranasal HDM cha

21 required in two different models to amplify eosinophilic airway inflammation via induced expression

22 Eosinophilic airway inflammation was not significantly d

23 CD11c-Cre mice have a phenotype of increased eosinophilic airway inflammation, allergic sensitization

24 During eosinophilic airway inflammation, approximately 30% of l

25 n patients with nonatopic asthma with severe eosinophilic airway inflammation, but did not affect spu

26 Signatures associated with eosinophilic airway inflammation, mast cells, and group

27 ic asthma, including airway hyperreactivity, eosinophilic airway inflammation, mucus hypersecretion,

28 t exposure of airways with HT-HDM induced an eosinophilic airway inflammation, Th2 cytokine productio

29 African American subjects exhibit greater eosinophilic airway inflammation, which might explain th

30 siveness is closely related to the degree of eosinophilic airway inflammation.

31 g depletion was significantly greater during eosinophilic airway inflammation.

32 ers of inflammation are poorly predictive of eosinophilic airway inflammation.

33 ed by increased levels of FeNO, a marker for eosinophilic airway inflammation.

34 ic corticosteroid treatment, and evidence of eosinophilic airway inflammation.

35 thma, is only active in patients with active eosinophilic airway inflammation.

36 needed for IL-33-induced ILC2 expansion and eosinophilic airway inflammation.

37 mune responses in the setting of HDM-induced eosinophilic airway inflammation.

38 three clinically relevant asthma phenotypes: eosinophilic allergic asthma, eosinophilic nonallergic a

39 respect to inflammatory phenotypes, 71% were eosinophilic and 25% mixed granulocytic.

40 ntial therapeutic target for EoE and related eosinophilic and allergic diseases.

41 interleukins 4, 5, and 13, as underlying the eosinophilic and allergic inflammatory processes in near

42 ions and that gammaT supplementation reduces eosinophilic and endotoxin (LPS)-induced neutrophilic ai

43 al control was associated with signatures of eosinophilic and granulocytic inflammatory signals, wher

44 reas as expected FeNO and ECP were higher in eosinophilic and mixed asthma, while IL-8 was higher in

45 Eosinophilic and mixed neutrophilic/eosinophilic inflamm

46 SRA occurred more frequently in the eosinophilic and mixed phenotype (41.6% and 43.7%, respe

47 e dust extracts as adjuvants developed mixed eosinophilic and neutrophilic airway inflammation and ai

48 Eosinophilic and neutrophilic asthma endotypes are also

49 rophilic; cluster 3: COPD predominant, mixed eosinophilic and neutrophilic.

50 tor for the development of asthma and may be eosinophilic and steroid-responsive or neurogenic and no

51 ular pathways involved in both patients with eosinophilic and those with noneosinophilic asthma.

52 L-HCCs: large polygonal cells with granular, eosinophilic, and mitochondria-rich cytoplasm, prominent

53 Benralizumab is an anti-eosinophilic, anti-interleukin-5 receptor alpha monoclon

54 n the mean age between patients with diffuse eosinophilic artifacts (1.7 months) and patients with on

55 43.84 pg/ml, P < 0.05) and in patients with eosinophilic as compared to mixed granulocytic phenotype

56 ma severity as follows: patients with severe eosinophilic asthma > patients with mild asthma approxim

57 8) (P=0.007) with highest levels observed in eosinophilic asthma (EA); median 0.22%, IQR 0.11%-0.47%;

58 patients aged 12 years or older with severe eosinophilic asthma and a history of at least two exacer

59 icacy of mepolizumab in patients with severe eosinophilic asthma and a history of exacerbations.

60 teroid insensitivity in patients with severe eosinophilic asthma and impaired macrophage scavenger fu

61 nflammation observed in patients with severe eosinophilic asthma and reveal CCL26 as a potential targ

62 t basophils may be particularly important in eosinophilic asthma and that sputum basophil assessment

63 r assess mepolizumab in patients with severe eosinophilic asthma by examining its effect on health-re

64 Patients with severe eosinophilic asthma have an exaggerated eosinophilopoeit

65 blood myeloid DC subsets from patients with eosinophilic asthma have lower LRP-1 expression than cel

66 sive and externally validated test to assess eosinophilic asthma in patients not on OCS.

67 antibodies was investigated in patients with eosinophilic asthma maintained on high-dose corticostero

68 ophil resolution and could contribute to the eosinophilic asthma phenotype.

69 own substantial benefit in patients with the eosinophilic asthma phenotype; so too have monoclonal an

70 antibody mepolizumab in patients with severe eosinophilic asthma previously treated with omalizumab.

71 analyses indicate that patients with severe eosinophilic asthma respond positively to mepolizumab re

72 P-1, eotaxin, and IL-8 discriminates between eosinophilic asthma severity clusters.

73 by circulating myeloid DCs in patients with eosinophilic asthma suggests a possible role for LRP-1 i

74 eukin-5 antibody for the treatment of severe eosinophilic asthma suggests that there will be a therap

75 potential target for treating patients with eosinophilic asthma that are refractory to classic thera

76 ncy room visit rates in patients with severe eosinophilic asthma treated with mepolizumab or placebo

77 with sputum IL-1beta protein levels, whereas eosinophilic asthma was associated with an IL-13-induced

78 will allow selection of patients with severe eosinophilic asthma who are most likely to achieve clini

79 The proposed prediction model identifies eosinophilic asthma without the need for sputum inductio

80 mprovements in HRQOL in patients with severe eosinophilic asthma, and had a safety profile similar to

81 ficant exacerbations in patients with severe eosinophilic asthma, compared with placebo.

82 to standard of care for patients with severe eosinophilic asthma, has been shown in previous studies

83 ate of exacerbations in patients with severe eosinophilic asthma.

84 ed for the treatment of patients with severe eosinophilic asthma.

85 ammation in patients with moderate-to-severe eosinophilic asthma.

86 e potential as an add-on treatment option in eosinophilic asthma.

87 of patients with mild and those with severe eosinophilic asthma.

88 prominent in BECs from patients with severe eosinophilic asthma.

89 ompared with placebo in patients with severe eosinophilic asthma.

90 ent with mepolizumab in patients with severe eosinophilic asthma.

91 other inflammatory phenotypes, particularly eosinophilic asthma.

92 educes exacerbations in patients with severe eosinophilic asthma.

93 roves lung function for patients with severe eosinophilic asthma.

94 to standard of care in patients with severe eosinophilic asthma.

95 to treat patients with severe, uncontrolled, eosinophilic asthma.

96 nct from the iEos isolated from the sputa of eosinophilic asthmatic patients (Siglec-8+CD62LloIL-3Rhi

97 thmatics (sputum neutrophils >/= 76%), while eosinophilic asthmatics (sputum eosinophils >/= 3%) did

98 sinophils and EoP numbers was made in severe eosinophilic asthmatics who participated in a randomized

99 Exosomes of severe eosinophilic asthmatics' fibroblasts can contribute to a

100 progenitors (EoP) were assayed in 21 severe eosinophilic asthmatics, 19 mild asthmatics, eight COPD

101 Neutrophilic, but not eosinophilic, asthmatics display overexpression of IFN-b

102 al course, the patient was suspected to have eosinophilic bronchiolitis.

103 The levels of IL-8, IL-13 and eosinophilic cationic protein (ECP) were also measured i

104 rom the histopathologic examination revealed eosinophilic, collagenous, round or ovoid bodies (sclero

105 d, GPTD does not resemble a granulomatous or eosinophilic condition.

106 lung function or qCT, but were increased in eosinophilic COPD.

107 at IL-2 was essential for the development of eosinophilic crystalline pneumonia, a type 2 disease cha

108 We examined the role of ILC2s in eosinophilic crystalline pneumonia, an idiopathic type 2

109 en Muller cell foot processes with intensely eosinophilic cytoplasm that mimicked erythrocytes of ner

110 Eo-MDSC exhibit eosinophilic cytoplasmic granules and express CD11b, the

111 ally been diagnosed by the presence of large eosinophilic cytoplasmic inclusions and is associated wi

112 ed in the treatment of inflammatory skin and eosinophilic diseases.

113 important implications for the treatment of eosinophilic disorders such as asthma.

114 treatment of allergic inflammation and other eosinophilic disorders.

115 exposed to a peanut regimen known to induce eosinophilic esophageal inflammation.

116 Eosinophilic esophagitis (EoE) afflicts both children an

117 responsive, representing 2 entities known as eosinophilic esophagitis (EoE) and PPI-responsive esopha

118 Eosinophilic esophagitis (EoE) exhibits esophageal dysfu

119 Eosinophilic esophagitis (EoE) has emerged over the past

120 Links between food allergens and eosinophilic esophagitis (EoE) have been established, bu

121 Eosinophilic esophagitis (EoE) is a chronic antigen-medi

122 Eosinophilic esophagitis (EoE) is a chronic disease char

123 Eosinophilic esophagitis (EoE) is a chronic TH2 inflamma

124 Eosinophilic esophagitis (EoE) is a chronic, immune/anti

125 Eosinophilic esophagitis (EoE) is a chronic, inflammator

126 Eosinophilic esophagitis (EoE) is a new disease.

127 Eosinophilic esophagitis (EoE) is a rapidly emerging, ch

128 Eosinophilic esophagitis (EoE) is a recently recognized

129 Eosinophilic esophagitis (EoE) is a severe inflammatory

130 Eosinophilic esophagitis (EoE) is a Th2 cytokine-associa

131 Eosinophilic esophagitis (EoE) is an allergic disease of

132 Eosinophilic esophagitis (EoE) is an emerging tissue-spe

133 Eosinophilic esophagitis (EoE) is an esophageal inflamma

134 Eosinophilic esophagitis (EoE) is an inflammatory disord

135 Although eosinophilic esophagitis (EoE) is associated with certai

136 Pharmacologic treatment of eosinophilic esophagitis (EoE) is limited to off-label u

137 ACKGROUND & AIMS: Pharmacologic treatment of eosinophilic esophagitis (EoE) is limited to off-label u

138 g studies have observed an increased risk of eosinophilic esophagitis (EoE) mostly among first-degree

139 Diagnostic evaluation of eosinophilic esophagitis (EoE) remains difficult, partic

140 Eosinophilic esophagitis (EoE) was historically distingu

141 ng eosinophilic tissue inflammation, such as eosinophilic esophagitis (EoE), a chronic inflammatory d

142 Eosinophilic esophagitis (EoE), a food antigen-mediated

143 The molecular and cellular etiology of eosinophilic esophagitis (EoE), an emerging tissue-speci

144 rs in the rapid increase in the incidence of eosinophilic esophagitis (EoE), but potential exposures

145 ated with pathological conditions, including eosinophilic esophagitis (EoE), in which basal progenito

146 be used to estimate the biologic activity of eosinophilic esophagitis (EoE).

147 f empiric elimination diets in patients with eosinophilic esophagitis (EoE).

148 elimination from the diets of patients with eosinophilic esophagitis (EoE).

149 herapy) and 20 controls, stored in the Swiss Eosinophilic Esophagitis Database (SEED) and Biobank, we

150 Eosinophilic esophagitis is an emerging disease that is

151 By contrast, eosinophilic esophagitis is characterized by low levels

152 wth factor beta production and signaling, to eosinophilic esophagitis pathophysiology.

153 Eosinophilic esophagitis patients were stratified based

154 (1) anaphylactic sensitivity to peanut, (2) eosinophilic esophagitis related to cow's milk, and (3)

155 The Pediatric Eosinophilic Esophagitis Symptom Score (PEESS v2.0) meas

156 gitis or nonerosive but pH-abnormal GERD) or eosinophilic esophagitis than in patients without GERD o

157 patients with eosinophilic skin diseases or eosinophilic esophagitis were used for in vivo analyses.

158 gion, rs3806932 (G allele protective against eosinophilic esophagitis) and rs2416257 (A allele associ

159 ergic rhinitis, allergic conjunctivitis, and eosinophilic esophagitis), suggesting both cutaneous and

160 ogenesis of many diseases, including asthma, eosinophilic esophagitis, and eczema.

161 verlap between symptoms of GERD and those of eosinophilic esophagitis, functional dyspepsia, and gast

162 Eosinophilic esophagitis-like esophageal inflammation wa

163 ophageal biopsy specimens from patients with eosinophilic esophagitis.

164 ng asthma, chronic rhinosinusitis (CRS), and eosinophilic esophagitis.

165 at in patients without GERD or patients with eosinophilic esophagitis; patients with GERD had low MI

166 Importance: Eosinophilic fasciitis (EF) is a connective tissue disor

167 in treating asthma patients with the severe eosinophilic form of the disease and are the first new c

168 istologic features among themselves and with eosinophilic gastroenteropathies.

169 Patients with eosinophilic gastrointestinal disease (EGID), patients w

170 However, the role of the microbiome in most eosinophilic gastrointestinal diseases (EGIDs) is not ye

171 Eosinophilic gastrointestinal disorders (EGIDs) are hype

172 to food allergens (e.g., food allergies and eosinophilic gastrointestinal disorders).

173 tic tumors are characterized by an excessive eosinophilic, granular cytoplasm due to aberrant accumul

174 Eosinophilic granulomatosis with polyangiitis (EGPA) is

175 ener's), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA, for

176 Eosinophilic granulomatosis with polyangiitis is an eosi

177 ed participants with relapsing or refractory eosinophilic granulomatosis with polyangiitis who had re

178 In participants with eosinophilic granulomatosis with polyangiitis, mepolizum

179 associated with EM were hypersensitivity and eosinophilic granulomatosis with polyangiitis, which acc

180 ounts and may have value in the treatment of eosinophilic granulomatosis with polyangiitis.

181 cut point to define subjects with either an eosinophilic (>/=2%) or noneosinophilic (<2%) inflammato

182 pic asthma with neutrophilic (>/=53%) and/or eosinophilic (>/=3%) airway inflammation.

183 cal clusters: cluster 1: asthma predominant, eosinophilic, high TH2 cytokines; cluster 2: asthma and

184 Protection against eosinophilic immunopathology by vaccines containing delt

185 associated with significantly increased lung eosinophilic immunopathology on day 6 postchallenge, thi

186 me also protects against development of lung eosinophilic immunopathology.

187 ed by food allergy and manifested by mucosal eosinophilic infiltration at any level of the gastrointe

188 We demonstrate that NK cells limit eosinophilic infiltration both indirectly, through alter

189 Eosinophilic infiltration has long been a histologic hal

190 giogenesis is closely linked to and precedes eosinophilic infiltration in asthma.

191 which is characterized histologically by an eosinophilic infiltration into the esophageal tissue.

192 It is a distinct syndrome associated with eosinophilic infiltration of respiratory tissues and exc

193 Lungs from these mice show strong eosinophilic infiltration, excessive Th2 polarization, m

194 Patients had evidence of eosinophilic inflammation >/=150 cells/mul (at screening

195 ss the effect of LPS on the allergen-induced eosinophilic inflammation [primary endpoints: eosinophil

196 oteases as adjuvants developed predominantly eosinophilic inflammation and AHR.

197 t contribution of PAR2 in the development of eosinophilic inflammation and airway hyperresponsiveness

198 Allergic asthma is characterized by eosinophilic inflammation and airway obstruction.

199 ce generated a similar phenotype of enhanced eosinophilic inflammation and allergic sensitization.

200 f3a gene increased the severity of pulmonary eosinophilic inflammation and expression of cytokines (I

201 L-6, TNF-alpha, and IL-17 in contrast to the eosinophilic inflammation and IL-4 production observed i

202 Some patients with COPD have predominantly eosinophilic inflammation and might respond to high dose

203 TH2-driven eosinophilic inflammation and neutrophil-associated infl

204 tics with a correlation between the baseline eosinophilic inflammation and the change in FEV1 .

205 chanism by which it initiates or facilitates eosinophilic inflammation appears to be largely independ

206 This case suggests the possibility that eosinophilic inflammation can occur concomitantly in the

207 tics had a lower FEV1 and Pc20 and increased eosinophilic inflammation compared to healthy subjects.

208 The severe group had a lower FEV1 and more eosinophilic inflammation compared to mild/moderate asth

209 vated RSV (FI-RSV) leads to prominent airway eosinophilic inflammation following RSV challenge; howev

210 lactis strain, able to attenuate esophageal eosinophilic inflammation in a preclinical model of EoE.

211 ne caused a similar degree of suppression of eosinophilic inflammation in all compartments in both gr

212 such, biomarkers currently used to delineate eosinophilic inflammation in asthmatic subjects should b

213 Clinical trials targeting eosinophilic inflammation in COPD should consider assess

214 e transfer experiments showed reduced airway eosinophilic inflammation in mice receiving OVA-sensitiz

215 lly deficient in Muc5b displayed exaggerated eosinophilic inflammation in response to intratracheal i

216 Identification of eosinophilic inflammation in the airways has become an i

217 dy levels, but type 2 cytokine responses and eosinophilic inflammation in the airways remained unaffe

218 oids, confirming the importance of measuring eosinophilic inflammation to guide corticosteroid use.

219 Eosinophilic inflammation was associated with but not li

220 Only baseline eosinophilic inflammation was associated with the physio

221 Eosinophilic and mixed neutrophilic/eosinophilic inflammation were more prevalent in patient

222 atients with asthma develop type-2 dominated eosinophilic inflammation, a number of individuals devel

223 sed goblet cell differentiation, spontaneous eosinophilic inflammation, and airway hyperresponsivenes

224 tionship between oxidative stress extension, eosinophilic inflammation, and disease severity in asthm

225 d intranasal challenges with OVA caused AHR, eosinophilic inflammation, and goblet cell hyperplasia i

226 ma include airway hyperresponsiveness (AHR), eosinophilic inflammation, and goblet cell metaplasia.

227 attenuates airway hyperresponsiveness (AHR), eosinophilic inflammation, and mucus-production response

228 rigger airway hyperresponsiveness, prominent eosinophilic inflammation, and significantly increased s

229 challenged mice exhibited enhanced bronchial eosinophilic inflammation, elevated IL-13 production, an

230 induce M2 polarization) were sufficient for eosinophilic inflammation, mucous metaplasia, and airway

231 In contrast to eosinophilic inflammation, neutrophilic inflammation was

232 otects mice from allergic asthma by reducing eosinophilic inflammation, serum IgE level, and T helper

233 ld-to-moderate asthma result in TH2-mediated eosinophilic inflammation, whereas patients with severe

234 llergen challenge phase for neutrophilic and eosinophilic inflammation.

235 eas wild-type mice had a purely TH2-mediated eosinophilic inflammation.

236 disease severity and the baseline extent of eosinophilic inflammation.

237 nasal polyps is characterized by TH2-biased eosinophilic inflammation.

238 such as disease severity, lung function, and eosinophilic inflammation.

239 nous epithelial cell metaplasia, and massive eosinophilic inflammation.

240 by airway hyperresponsiveness (AHR) without eosinophilic inflammation.

241 T(H)2 cell subpopulation underlying allergic eosinophilic inflammation.

242 or house dust mite extract (HDM) and induce eosinophilic inflammation.

243 ize their function in patients with allergic eosinophilic inflammatory diseases.

244 erbated respiratory disease (AERD), a severe eosinophilic inflammatory disorder of the airways, invol

245 atic source for protein carbamylation during eosinophilic inflammatory models, including aeroallergen

246 The diagnosis chronic eosinophilic leukemia, not otherwise specified (CEL, NOS

247 sociated with FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.

248 mation after allergen exposure, with massive eosinophilic lung infiltrates and increased Th2 cytokine

249 pates in the progression of allergen-induced eosinophilic lung inflammation to corticosteroid-refract

250 e lacking PTX3 have exaggerated neutrophilic/eosinophilic lung inflammation, mucus production, and ai

251 We describe the first 2 cases of eosinophilic meningitis due to Paragonimus kellicotti.

252 sis was responsible for 67.3% of 55 cases of eosinophilic meningitis from a cohort of 1,690 adult pat

253 ngylus cantonensis, while a primary cause of eosinophilic meningitis, is rarely a cause of FUO.

254 (60.0-85.5) vs 80.5 (69.7-95.0), P=.009] for eosinophilic, mixed, neutrophilic and paucigranulocytic

255 autolytic postmortem histologic artifact of eosinophilic Muller cell foot process swelling that mimi

256 Eosinophilic myocarditis (EM) is an acute life-threateni

257 in hypereosinophilic IL-5Tg mice resulted in eosinophilic myocarditis with severe ventricular and atr

258 Patients with giant-cell myocarditis, eosinophilic myocarditis, or cardiac sarcoidosis and tho

259 rmined in 167 participants and classified as eosinophilic (n = 84), neutrophilic (n = 14), paucigranu

260 granulocytic (n = 60), or mixed neutrophilic-eosinophilic (n = 9) asthma phenotypes.

261 Patients with eosinophilic nasal polyposis frequently require surgery,

262 ic damage occurred 72 hours after treatment; eosinophilic necrotic plugs formed within sebaceous glan

263 rent asthma phenotypes have been recognized (eosinophilic, neutrophilic, mixed and paucigranulocytic)

264 ma phenotypes: eosinophilic allergic asthma, eosinophilic nonallergic asthma and noneosinophilic nona

265 Exclusion criteria included eosinophilic oesophagitis and severe asthma.

266 ardinal features of asthma in the absence of eosinophilic or neutrophilic inflammation.

267 lar (P = .005) in neutrophilic compared with eosinophilic participants.

268 uals when infected by virus can develop lung eosinophilic pathology, a problem that is further exacer

269 yloid plaques are also present in tissues of eosinophilic patients in a feedback mechanism that likel

270 to the steroid-unresponsive nature of these eosinophilic patients.

271 ous CALR mutation and were also deficient in eosinophilic peroxidase (EPX).

272 dified intention-to-treat population with an eosinophilic phenotype (462 patients) was 1.40 per year

273 over a 1-year period than those with the non-eosinophilic phenotype based on the univariable and mult

274 Subjects with the persistently eosinophilic phenotype had a significantly shorter time

275 ased exacerbation risk compared with the non-eosinophilic phenotype in severe asthma.

276 The persistent eosinophilic phenotype is associated with increased exac

277 obstructive pulmonary disease (COPD) with an eosinophilic phenotype may benefit from treatment with m

278 dified intention-to-treat population with an eosinophilic phenotype were stratified according to bloo

279 of a murine allergic airway diseases with an eosinophilic phenotype.

280 than placebo among patients with COPD and an eosinophilic phenotype.

281 te subjects in either group (percentage with eosinophilic phenotype: ICS+ group: 19% vs 16%, P = .28;

282 Chronic eosinophilic pneumonia complicated with Mycoplasma pneum

283 s treated with lebrikizumab and one event of eosinophilic pneumonia in the placebo group.

284 systemic disorders such as granulomatous or eosinophilic polyangiitis, and sarcoidoisis.

285 Altogether, we define a new pathway of eosinophilic regulation through interactions with NK cel

286 hma subtype, is characterized by exaggerated eosinophilic respiratory inflammation and reactions to a

287 en shown to induce a CD4(+) T cell-dependent eosinophilic response in the lung capable of providing p

288 sthma-like lung pathology, given the natural eosinophilic response to infection.

289 ting in the suppression of a protective host eosinophilic response.

290 ese animals displayed unaltered lung Th2 and eosinophilic responses after intranasal HDM challenge an

291 -33, group 2 innate lymphoid cell (ILC2) and eosinophilic responses to Alternaria allergen administra

292 aria allergen administration, and diminished eosinophilic responses to Nippostrongylus brasiliensis,

293 IL1RL1 gene expression is associated with eosinophilic SA, whereas NLRP3 inflammasome expression i

294 Tissue samples of patients with eosinophilic skin diseases or eosinophilic esophagitis w

295 rogrammed to skew allergic inflammation from eosinophilic T helper cell 2 (TH2) to neutrophilic TH17

296 del, we found that wild-type mice develop an eosinophilic Th2 airway disease in response to A. altern

297 processes, notably for this review involving eosinophilic tissue inflammation, such as eosinophilic e

298 en shown to generate so-called extracellular eosinophilic traps (EETs) under similar pathologic condi

299 The presence of eosinophilic (type 2) inflammation in some but not all p

300 hilic granulomatosis with polyangiitis is an eosinophilic vasculitis.